{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:44:25Z","timestamp":1747226665958,"version":"3.40.5"},"reference-count":8,"publisher":"Weston Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Objective: To determine if the agonistic effects of buprenorphine and methadone affect drug use.\r\nMethod: Quantitative examination of urine drug concentrations of patients treated with buprenorphine and methadone.\r\nResults: Patients on buprenorphine had less opioid and methamphetamine drug use than those on methadone.\r\nConclusion: Patients on buprenorphine therapy appear to use less illicit drugs.<\/jats:p>","DOI":"10.5055\/jom.0861","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T23:22:29Z","timestamp":1720826549000},"page":"193-195","source":"Crossref","is-referenced-by-count":0,"title":["Observations on the effects of buprenorphine and methadone on illicit drug use"],"prefix":"10.5055","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-9703","authenticated-orcid":false,"given":"Amadeo J.","family":"Pesce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Krock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Cua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"90870","unstructured":"US Department of Veterans Affairs: VA\/DoD clinical practice guidelines. 2021. Available at https:\/\/www.healthquality.va.gov\/guidelines\/mh\/sud\/. Accessed April 29, 2024."},{"key":"90871","unstructured":"Amadeo P, Raymond S, Dennis R, et al.: Effects of a pandemic and isolation on alcohol and psychoactive medication use in a population of rehabilitation and pain patients annals of clinical & laboratory science. Ann Clin Lab Sci. 2021; 51(5): 694-697."},{"key":"90872","doi-asserted-by":"crossref","unstructured":"Krock, K, Pesce A, Ritz D, et al.: Lower cutoff for LC-MS\/ MS urine drug testing indicates better patient compliance. Pain Physician. 2017; 20: E1107-E1113.","DOI":"10.36076\/ppj\/2017.7.E1107"},{"key":"90873","unstructured":"Pesce AJ, Chandler N, Ackerman G: Information technology structure for urine drug testing reports 21ST century pathology 2021 21CP-1-103.pdf. Available at 21stcenturypathology.com. Accessed April 29, 2024."},{"key":"90874","doi-asserted-by":"crossref","unstructured":"Vigezzi P, Guglielmino L, Marzorati P, et al.: Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat. 2006; 31: 3-7.","DOI":"10.1016\/j.jsat.2006.03.007"},{"key":"90875","doi-asserted-by":"crossref","unstructured":"Montoya ID, Gorelick DA, Preston KL, et al.: Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004; 75(1): 34-48. DOI: 10.1016\/j.clpt.2003.09.004.","DOI":"10.1016\/j.clpt.2003.09.004"},{"key":"90876","doi-asserted-by":"crossref","unstructured":"Furo H, Wiegand T, Rani M, et al.: Association between buprenorphine dose and the urine \u201cnorbuprenorphine\u201d to \u201ccreatinine\u201d ratio: Revised. Subst Abuse. 2023; 17: 117822182311537. DOI: 10.1177\/11782218231153748.","DOI":"10.1177\/11782218231153748"},{"key":"90877","doi-asserted-by":"crossref","unstructured":"Furo H, Schwartz DG, Sullivan RW, et al.: Buprenorphine dosage and urine quantitative buprenorphine, norbuprenorphine, and creatinine levels in an office-based opioid treatment program. Subst Abuse. 2021; 15: 11782218211061749.","DOI":"10.1177\/11782218211061749"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3660\/3947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3660\/3947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T23:22:35Z","timestamp":1720826555000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6,28]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0861","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"type":"electronic","value":"1551-7489"},{"type":"print","value":"1551-7489"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}